Skip to main content

Table 1 MPTP mouse model groups

From: The potassium channel KCa3.1 represents a valid pharmacological target for microgliosis-induced neuronal impairment in a mouse model of Parkinson’s disease

Groups (n = 10–15/group)

Treatment (day1–5)

Control

Vehicle

MPTP

20 mg/kg, once daily, i.p. day1–5

MPTP+senicapoc

MPTP (20 mg/kg, once daily, i.p. day1–5) + senicapoc (100 mg/kg, once daily, p.o. day1–5, 1 h prior to MPTP exposure)

Senicapoc

100 mg/kg, once daily, p.o. day1–5

WT

Vehicle

KCa3.1−/−

Vehicle

WT+MPTP

20 mg/kg, once daily, i.p. day1–5

KCa3.1−/−+MPTP

20 mg/kg, once daily, i.p. day1–5